Effects of Anti-VEGF Targeted Drugs on Patients' Blood Pressure and Endothelial Function

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

30 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-07-05

Study Completion Date

2021-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Explore the effects of anti-VEGF targeted drugs on blood pressure and endothelial function in cancer patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Endothelial Effects of VEGF Inhibition In Vivo in Man

NCT03557190

Cardiovascular Diseases

COMPLETED

The Adherence to Oral Anticoagulant in Chinese Patients With NVAF

NCT04942873

Nonvalvular Atrial Fibrillation

UNKNOWN

A Prospective Study to Evaluate the Effect of Chronic Nitrate Therapy on Vasodilation Function in Coronary Heart Disease

NCT01430780

Coronary Artery Disease

UNKNOWN

Real World Assessment of Effects of Beta-blockers on Patients With Acute Coronary Syndrome

NCT03669991

Acute Coronary Syndrome

UNKNOWN

Prevention of Left Ventricular Dysfunction During Chemotherapy

NCT01110824

Acute Myeloid Leukemia Precursor-cell Lymphoblastic Leukemia-Lymphoma Lymphoid Neoplasm +3 more

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Thirty tumor patients with anti-VEGF drugs were selected. Demographic information and clinical information of all patients were collected before chemotherapy. Ambulatory blood pressure monitoring and endothelial function measurement (PWV, EndoPAT) were performed. Ambulatory blood pressure and PWV were reviewed at 2 weeks and 1 month. And EndoPAT, to evaluate the effects of anti-VEGF drugs on blood pressure and endothelial function in cancer patients.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cardiac Toxicity VEGF Endothelial Dysfunction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Tumor patients using anti-VEGF drugs

Anti-VEGF

Intervention Type DRUG

Anti-tumor drugs targeting the vascular endothelial growth factor (VEGF) signaling pathway

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Anti-VEGF

Anti-tumor drugs targeting the vascular endothelial growth factor (VEGF) signaling pathway

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Tumor patients using anti-VEGF drugs

Exclusion Criteria

* Hypertension, coronary heart disease, valvular heart disease, cardiomyopathy and other organic heart diseases, exclude liver and kidney failure, severe cerebrovascular disease, chronic obstructive pulmonary disease, rheumatic immune system disease

Eligible Sex

ALL

Accepts Healthy Volunteers

No